A "nema" of hope in the treatment of late-onset nemaline myopathy

Neurology

Volumn 71, Issue 7, 2008, Pages 472-473

  Dalakas, Marinos C ^a,b   Smith, Stephen A ^c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d GILLETTE CHILDREN'S SPECIALTY HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ; AMYLOID; IMMUNOGLOBULIN; LENALIDOMIDE; MELPHALAN; NEBULIN; THALIDOMIDE; TROPONIN; MYELOABLATIVE AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BREATHING; CLINICAL EFFECTIVENESS; DAILY LIFE ACTIVITY; DYSPHAGIA; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFLAMMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; NEMALINE MYOPATHY; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; RESPIRATORY FAILURE; TREATMENT RESPONSE; ADULT; CLINICAL TRIAL; NOTE; ONSET AGE; STEM CELL TRANSPLANTATION;

ADULT; AGE OF ONSET; CLINICAL TRIALS AS TOPIC; HUMANS; MELPHALAN; MYELOABLATIVE AGONISTS; MYOPATHIES, NEMALINE; STEM CELL TRANSPLANTATION;

EID: 53749099012     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000324861.44410.be     Document Type: Editorial

References (11)

1. Chahin N, Selcen D, Engel AG. Sporadic late onset nemaline myopathy. Neurology 2005;65:1158-1164.
2. Keller CE, Hays AP, Rowland LP, et al. Adult-onset nemaline myopathy and monoclonal gammopathy. Arch Neurol 2006;63:132-134.
3. Sanoudou D, Frieden LA, Haslett JN, et al. Molecular classification of nemaline myopathies: "nontyping" specimens exhibit unique patterns of gene expression. Neuro-biol Dis 2004;15:590-600.
4. Eymard B, Brouet JC, Collin H, et al. Late-onset rod myopathy associated with monoclonal gammopathy. Neuromuscul Disord 1993;3:557-560.
5. Dalakas MC, Pezeshkpour GH, Flaherty M. Progressive nemaline (rod) myopathy associated with HIV infection. N Engl J Med 1987;317:1602-1603.
6. Benveniste O, Laforet P, Dubourg O, et al. Stem cell transplantation in a patient with late-onset nemaline myopathy and gammopathy. Neurology 2008;71:531-532.
7. Voermans NC, Minnema M, Lammens M, et al. Sporadic late-onset nemaline myopathy effectively treated by mel-phalan and stem cell transplant. Neurology 2008;71:532- 534.
8. Jaccard A, Moreau P, Leblond V, et al. High-dose melpha-lan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-1093.
9. Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998; 55:1509- 1512.
10. Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 2008;131: 1228-1240.
11. Dalakas MC, Rakocevic G, McElroy B, et al. Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) alters disease progression and suppresses endomysial inflammation. Ann Neurol 2007;62: 560-565.